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ABSTRACT 
The primary goal of the conducted research was to analyse the role of lymphatic 
endothelial cell in heart failure as well as in the setting of heart and lung 
transplantation. 
Our observations of lymphatic phenotype after heart and lung transplantation in 
human patients are the first of their kind and provide the evidence, that acute 
allograft rejection is associated with significant changes of lymphatic endothelial 
phenotype. 
In experimental studies, we demonstrated that ischemia-reperfusion injury activated 
the lymphatic endothelium in cardiac allografts. The process was mediated by 
interaction in the VEGF-C and VEGFR-3 axis and had direct consequences for the 
development of alloimmune responses. Furthermore, specific perioperative single-
dose VEGF-C inhibition demonstrated beneficial effects on lymphatic vessel 
activation, antigen-presenting cell transport and subsequent alloimmune responses 
in cardiac allografts. 
The results of the studies, thus, demonstrate the significance of VEGF-C-VEGFR-3 
signaling in promotion of alloimmunity and suggest VEGF-C/D inhibiting strategies as 
an alternative clinically feasible lymphatic vessel targeted immunomodulatory 
approach.  
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INTRODUCTION 
Transplantation is a well established and often the final therapeutic option for the 
patients with end-stage heart and lung failure. The various advances in 
immunosuppression and human leucocyte antigen matching techniques have 
significantly reduced the incidence of acute allograft rejection, whereas the chronic 
allograft rejection is still difficult to treat and causes the absolute majority of terminal 
graft failure. Lymphatic endothelium is important in the pathogenesis of various 
cardiac and pulmonary diseases. However, the exact knowledge about the functions 
and role of lymphatic endothelium in heart and lung failure as well as after 
transplantation is still lacking. Therefore, the study focused on the investigation of the 
changes of lymphatic endothelial phenotype in patients with terminal heart failure and 
after heart and lung transplantation. Further, the mechanisms of lymphatic 
endothelial activation in the ischemia-reperfusion injury were evaluated in 
experimental rat and mouse cardiac transplantation. Finally, novel clinically feasible 
strategies of lymphatic endothelial activation inhibition were tested in experimental 
models. 
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REVIEW OF THE LITERATURE 
1 Clinical heart transplantation 
Christian Barnard, assisted by Rodney Hewitson, was the first surgeon worldwide to 
successfully transplant a human heart on the 3rd December of 1967. The operation 
took place in Cape Town, at the Groote Schuur Hospital (Barnard 1967). Louis 
Washkansky, the first human recipient of a heart transplant, died 18 days after the 
transplantation on pneumonia. Nevertheless, the era of clinically feasible heart 
transplantation had begun, significantly promoted by Drs. Shumway and Lower (who 
previously built up the theoretical platform and developed the surgical techniques of 
heart transplantation in Stanford), as well as Drs. Demikhov, Ross, Cooley, 
Kantrowitz and other dedicated surgeons. Further improvement of operative 
techniques, postoperative care, and especially the wide introduction of 
immunosuppressant Cyclosporine A (CsA) (Borel et al. 1976) has made the 
procedure clinically relevant. Currently, heart transplantation is a valid therapeutic 
option for end-stage heart failure and approximately 4000 procedures are reported 
annually (Stehlik et al. 2012). 
1.1 Indications 
Nowadays, non-ischemic cardiomyopathy is the leading diagnosis in adult patients 
undergoing heart transplant (54%), followed by ischemic cardiomyopathy (37%). The 
remaining indications for heart transplantation are congenital heart failure (3%), 
valvular heart disease (3%) or repeated transplantation (3%). The majority of 
transplanted patients is 40 to 60 years of age and recipients older than 60 years of 
age are being transplanted with increasing frequency, which results from a 
combination of changing demographics of the general population, as well as the 
willingness of clinicians to transplant higher risk patients (Stehlik et al. 2012). 
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1.2 Survival 
Currently, the median survival for the entire cohort of adult and pediatric heart 
recipients who completed more than one year of follow-up is almost 10 years. 
Patients who live past the first year post-transplant have a 63% likelihood of being 
alive 10 years post-transplant and a 27% chance of being alive 20 years post-
transplant. Further, the survival rates have continuously been improving over the last 
3 decades. Most of this survival improvement is related to mortality reduction during 
the first post-transplant year. The patient survival stratified by different era is 
represented in the Figure 1. It is likely that interventions resulting in a reduction of 
events leading to long-term mortality will be needed to achieve further improvements 
in survival after heart transplant (Stehlik et al. 2012). 
 
 
Figure 1. Kaplan-Meier survival depending on the era for adult heart transplantation. 
Data from the ISHLT Registry (Stehlik et al. 2012). 
 
1.3 Complications and comorbidity 
The leading causes of death after transplant are acute rejection, graft failure, cardiac 
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allograft vasculopathy (CAV), infection, renal failure and malignancy. The relative 
contribution of these etiologies to post-transplant mortality changes with time elapsed 
since transplant (summarized in Table 1). Graft failure and infection are currently the 
leading causes of death in patients dying during the first 3 years after heart 
transplantation. Beyond approximately 3 years after transplant, malignancy and 
cardiac allograft vasculopathy become the major contributors to mortality. 
Interestingly, acute rejection has been directly responsible for only a minority of 
deaths; however, it is likely that consequences of acute rejection as well as chronic 
immune injury are responsible for deaths denoted as “graft failure” mortality (Stehlik 
et al. 2012). 
 
Table 1. Contribution of death causes to mortality by time since heart transplantation 
 
 
Cause of death 
Time after heart transplantation 
0-30 days 31 days –  
1 year 
>1-3 years >3-5 years >10 years 
Acute rejection 4% 9% 12% 5% 1% 
CAV 1% 3% 10% 10% 13% 
Graft failure 34% 17% 27% 25% 16% 
Renal failure 0% 1% 2% 4% 9% 
Infections (Non-
CMV) 
13% 29% 14% 11% 11% 
Malignancy 0% 3% 11% 20% 23% 
 
2 Clinical Lung transplantation 
James Hardy performed the first lung transplantation in a human in 1963 in 
University of Mississippi Medical Center (HARDY et al. 1963). It has needed a lot of 
effort to give the procedure a worldwide clinical acceptance as a valid therapeutic 
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tool for end-stage lung failure. As well as in case of heart transplantation, first the 
invention and clinical use of CsA allowed the wide and clinically relevant application 
of the procedure. So, over 3,5 thousands lung transplantations were performed in 
2010. The constantly growing number of procedures was largely the result of growing 
numbers of bilateral lung transplants, while the numbers of single-lung 
transplantations mainly remained on the same level (Christie et al. 2012). 
 
2.1 Indications 
Lung transplantation is a valid therapeutic tool for patients with severe end-stage 
lung failure. Following lung diseases are mainly underlying the the end-stage lung 
failure: chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary 
arterial hypertension and idiopathic interstitial pneumonia (Arcasoy and Kotloff 1999). 
Most procedures performed between January 1995 and June 2011 were indicated in 
34% for chronic obstructive pulmonary disease, in 23% for idiopathic pulmonary 
fibrosis, in 17% for cystic fibrosis and in 6% for alpha-1-antitrypsin-deficiency 
emphysema. Bilateral transplantation accounted for the largest proportion of 
transplant procedures (74%) across all age groups and diagnoses in 2010 (Christie 
et al. 2012). 
 
2.2 Survival 
According to current reports (Christie et al. 2012), overall median survival is 5.5 
years. The unadjusted survival rate at three months is currently 88%, at 1 year – 
79%, at 3 years – 64%, at 5 years – 53% and at 10 years – around 30% (Figure 2). 
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Figure 2. Kaplan-Meier survival depending on the type of procedure in adult lung 
transplants. Data from the ISHLT Registry (Christie et al. 2012). 
 
2.3 Complications and comorbidity 
Graft dysfunction and infections are the major causes of death within the first month 
and during the first year after lung transplantation. The most common causes of 
death after the first year were bronchiolitis obliterans and non-CMV infections.  Late 
deaths were reported as “graft failure” and are generally difficult to classify. Most 
likely, the graft failure might be associated with graft rejection or BOS. Further, the 
rate of reported deaths due to malignant tumors permanently increases with the time 
after the transplantation (Christie et al. 2012). 
The immunosuppressive medication is mainly causing the common comorbidities 
such as hypertension, renal dysfunction, diabetes, and hyperlipidaemia. The 
incidence of severe renal dysfunction among survivors is substantial and reaches a 
reported incidence of 14.4% at 10 years. 
BOS remains a common long-term complication. It is reported in every second 
recipient at 5 years after transplantation, increasing up to 76% at 10 years. Further, 
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malignancies are common after lung transplantation. At least one case of malignancy 
is reported in 14% of surviving recipients at 5 years and almost 30% at 10 years. As 
seen in prior years, skin and other cancers become more common than lymphoma 
as the interval from transplantation increases (Christie et al. 2012). 
 
3 Immunobiology of thoracic transplantation 
The various advances in immunosuppression and MHC matching techniques have 
significantly reduced the incidence of acute allograft rejection, whereas the chronic 
allograft injury remains a serious problem and causes the absolute majority of 
terminal graft failure (Christie et al. 2012; Stehlik et al. 2012). Thus, it is important 
that the development of chronic injury can take its origin even before the 
transplantation as a consequence of donor brain death and allograft ischemia. 
Furthermore, implantation and reperfusion of the allograft induces injury-related 
stress responses, which in turn initiate the alloimmune response (Wood and Goto 
2012). In other words, local allograft damage and ischemia-reperfusion injury 
activates of the non-specific innate immunity system. This marks the allograft as a 
site of damage and inflammation and leads to the activation of the more specific 
adaptive immunity, finally setting the scene for allograft rejection. 
3.1 Innate immunity 
Innate immunity is a rapid immunological response with limited specificity and no 
memory. Innate immunity includes cellular (neutrophils, macrophages, dendritic cells 
and natural killer cells) and molecular components (toll-like receptors, complement 
proteins, chemokines, cytokines and others) (Cristofaro and Opal 2006; Murphy et al. 
2011; Trouw and Daha 2011). Local tissue damage and ischemia reperfusion injury 
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leads to secretion of potential damage-associated molecular patterns (DAMPS). 
Following DAMPs are relevant in transplantation: reactive oxygen species, heat 
shock proteins, heparin sulphate, high mobility group box-1 and fibrinogen. DAMPs 
can bind to pathogen-associated pattern recognition receptors (PRRs), which are 
expressed on the surface of inflammatory cells (Wood and Goto 2012). This binding 
reaction further induces the production of pro-inflammatory cytokines, such as 
interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), interferons and chemokines 
(Carvalho-Gaspar et al. 2005; Lo et al. 2011). The following inflammation of the 
allograft modifies the vascular permeability and the endothelial cells viability. Further 
release of complement, acute phase proteins and graft antigens stimulate the exit of 
antigen-presenting cells (APCs) from the allograft towards recipient’s secondary 
lymphoid organs (Larsen et al. 1989; van Kooten et al. 2011), initiating the 
consequent allorecognition and adaptive immune responses. 
3.2 Adaptive Immunity 
Adaptive immunity comprises allorecognition, T- and B-cell activation and 
differentiation and effector destruction mechanisms. Adaptive immunity is slow, but 
has a high specificity and long-term memory. 
3.2.1 Allorecognition and T-cell activation 
The recognition of an alloantigen by T-cells (defined as allorecognition) is the 
beginning of immune response to allograft. 
T-cell activation occurs upon binding to their specific MHC antigens, which are 
usually expressed on antigen-presenting cells. Appropriate costimulatory molecules 
on the surface of APC, such as CD40, CD80 or CD86, are required. (Sayegh and 
Turka 1998; Clarkson and Sayegh 2005). 
Transplantation represents a very special immunological situation, where priming of 
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recipient T cells can occur by three different pathways (Afzali et al. 2008): direct, 
indirect and semidirect allorecognition. The interaction of recipient´s T-cell receptor 
with allogeneic MHC complexes, which are presented by donor APCs, is defined as 
direct allorecognition. The same process with the presentation of degraded donor 
MHC peptides by recipient APCs is defined as indirect allorecognition. And the 
uptake and presentation of donor antigens by recipient APCs is defined as semi-
direct allorecognition. 
In case of MHC-mismatched transplantation, the direct allorecognition is mainly 
involved in the initiation of the adaptive immune responses. However, due to the 
limited number of donor APCs transferred from an allograft, the direct allorecognition 
is only relevant for the initial phase of allograft rejection. The indirect pathway, on the 
other hand, remains maintained for the whole lifetime of the transplanted organ 
(Wood and Goto 2012). 
T-cell activation that is not accompanied by costimulatory signals can lead to further 
deletion of these T-cells. Alternatively, these T-cells can differentiate into protective 
regulatory cells (Tregs), which are capable of inhibiting cellular immune responses 
and are believed to be essential for prevention of autoimmune disease (Long and 
Buckner 2011; Heeger and Dinavahi 2012) 
 
3.2.2 T-cell differentiation 
Successful T-cell activation initiates a cascade of intracellular signaling pathways that 
lead to secretion of interleukin 2 (IL-2) and further T-cell proliferation and 
differentiation to effector cells. 
One important subset of effector T-cells are the CD4+ T-cells with helper function 
(Th). Several subgroups of Th cells exist and are referred to as Th1, Th2, Th17, Th9, 
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and Tfh (follicular helper) populations. 
Second important subset of effector T-cells are CD8+ T cells with cytotoxic activity 
(Tc). They are divided into Tc1 and Tc2 (Burrell and Bishop 2010; Wood and Goto 
2012). 
The activated effector T-cells acquire the ability to travel towards the sites of 
inflammation, directed by chemoattractant chemokines. Here, the specific target cells 
antigens can be recognized, which launces the effector mechanisms (release of 
proinflammatory cytokines and cytolytic killing). As a result, the antigen-expressing 
cells are destructed (Heeger and Dinavahi 2012). 
3.2.3 B-cell Activation 
B cells are multifunctional, as they mainly secrete antibodies but can also present 
antigens by expressing MHC and even secrete costimulatory molecules (Tarlinton et 
al. 2008). B cells can facilitate antigen presentation and so regulate the adaptive 
immunity (Carroll 2004). And serving as APC, B-cells are capable of communication 
with T-cells. Furthermore, B-cells require T-cell help for their activation and antibody 
production (Cyster 2010). 
The importance of antibody-mediated rejection is increasingly becoming evident 
nowadays (Montgomery et al. 2011). Experimental B-cell deficiency or disturbed 
production of donor-specific antibodies are beneficial for cardiac allograft survival 
(Brändle et al. 1998; Wasowska et al. 2001). In clinical setting, the diagnosis of 
antibody-mediated cardiac allograft rejection is defined as the allograft dysfunction 
combined with the histological evidence of C4d complement deposits on the 
capillary endothelium and macrophages in the capillary lumen in endomyocardial 
biopsies, together with the presence of donor-specific antibodies (Behr et al. 1999). 
Although very l i t t le is currently known about the influence of antibody-
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mediated rejection on the outcome after heart transplantation in adults, it seems to 
be significantly associated with reduced allograft survival after paediatric heart 
transplantation (Everitt et al. 2012).??
 
3.2.4 Lymphatic endothelium linking innate and adaptive immunity 
In the perspective of the current study, it is important to underline, that the 
development of alloimmune response after organ transplantation requires the 
migration of antigen presenting cells from allografts to secondary lymphoid organs 
(Larsen et al. 1990; Lakkis et al. 2000). Both, donor and recipient derived APCs, 
travel towards secondary lymphoid organs via the afferent lymphatics of the allograft, 
which they use as an exit from the allograft. Thus, allograft lymphatics are specifically 
important in a setting of transplantation, linking the innate and adaptive immunity 
(Figure 3).  
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Figure 3. Schematic overview of the alloimmunity initiation in the setting of 
cardiac transplantation. The migration of antigen presenting cells from vascularized 
allografts to secondary lymphoid organs is the first step in the initiation of alloimmune 
response after organ transplantation. Antigen-presenting cells enter the afferent 
lymphatics of the allograft and use them as an exit from the transplanted graft. The 
allorecognition takes place in secondary lymphoid organs. The activated effector 
cells migrate to the allograft and lead here to alloimmune response. Figure authored 
by Alexey Dashkevich, copyright by John Wiley and Sons; reprinted with permission. 
 
This phenomenon is very well described for the various inflammatory states. So, in 
contact hypersensitivity, inflamed lymphatic endothelium of the skin promotes the exit 
of leukocytes from tissue to afferent lymph through newly induced expression of the 
adhesion molecules ICAM-1 and VCAM-1 (Johnson et al. 2006). Inflammation-
induced lymphangiogenesis is considered to represent an endogenous anti-
inflammatory mechanism aimed at limiting edema formation and accumulation of 
inflammatory cells (Huggenberger et al. 2010). For example, lymphatic activation is 
beneficial in case of acute skin inflammation (Huggenberger et al. 2011) and 
stimulation of lymphangiogenesis inhibits chronic skin inflammation (Huggenberger et 
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al. 2010). Similarly, promotion of lymphangiogenesis benefits the treatment of 
asthma and other inflammatory airway diseases (Baluk et al. 2005). However, the 
functions and biology of lymphatic endothelium in the setting of terminal heart and 
lung failure and after transplantation are barely known. Thus, it was the main focus of 
this study. 
 
4 VEGF family 
4.1 Overview of the VEGF family members 
VEGF-A was discovered as a vascular permeability inducing tumour-secreted factor 
and was first named vascular permeability factor (Senger et al. 1983). Currently, five 
ligands belonging to the VEGF family are known: placental growth factor (PlGF), 
VEGF-A, VEGF-B, VEGF-C and VEGF-D (Jeltsch et al. 1997; Carmeliet and Jain 
2011; A. Alitalo and Detmar 2011 Dec 19; Koch and Claesson-Welsh 2012). 
Following VEGF receptors are known nowadays: VEGFR-1, VEGFR-2, VEGFR-3 
and neuropilins (NRP-1 and NRP-2). The general properties of VEGF ligands and the 
principal effects of VEGF receptors are combined in Figure 4. Simplified, the 
preferential expression of VEGFR-1 and -2 is restricted to blood vascular endothelial 
cells (EC) and of VEGFR-3 – to lymphatic EC. 
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Figure 4. VEGF ligands and receptors. VEGF ligands are binding to specific VEGF 
receptors. VEGFR-1 is expressed on endothelial cells and attracts monocytes and 
smooth muscle cells. VEGFR-2 is highly relevant for mitogenic effects on vascular 
endothelial cells. VEGFR-3 mainly controls the development and functionality of 
lymphatic endothelial cells and migration of antigen-presenting cells. PlGF, placental 
growth factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
Figure authored by Alexey Dashkevich, copyright by John Wiley and Sons; reprinted 
with permission. 
 
4.1.1 Angiogenic VEGF ligands and receptors 
The core receptors of VEGF-A are VEGFR-1, VEGFR-2, NRP-1 and NRP-2. 
Vascular and inflammatory cells in a variety of adult tissues are a rich source of 
VEGF-A. Its secretion is induced by hypoxia, inflammation and different growth 
factors (Tomizawa et al. 1984; Ferrara et al. 1990; Berse et al. 1992; Freeman et al. 
1995; McCourt et al. 1999; Melter et al. 2000). VEGF-A signalling leads to 
angiogenesis, which is a result of endothelial cell migration, proliferation and 
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sprouting. The angiogenic function of VEGF-A is pivotal for vascular development 
during embryogenesis (Carmeliet et al. 1996; Ferrara et al. 1996). 
Several directions of clinical use of VEGF-related therapeutic targets are of special 
interest. For instance, anti-VEGF targeting for the treatment of malignancies and eye 
disease have been suggested (Carmeliet and Jain 2011). Although this filed appears 
to be promising, the clinical use could not be established because of the lacking 
proof of evidence (Giacca and Zacchigna 2012).  
The core receptors of VEGF-B are VEGFR-1 and NRP-1. The main expression sites 
of VEGF-B are skeletal muscles and myocardium (Olofsson, Pajusola, Euler, et al. 
1996; Olofsson, Pajusola, Kaipainen, et al. 1996; Carmeliet and Jain 2011; Koch 
2012). VEGF-B is not critical for vascular development, as lack of VEGF-B doesn´t 
result in vascular malformation, but can lead to conducting defects and cardiac size 
reduction. (Bellomo et al. 2000; Aase et al. 2001; A. Alitalo and Detmar 2011 Dec 
19). Importantly, VEGF-B is an important player in cardiac arteriogenesis (Bry 2010; 
Koch and Claesson-Welsh 2012) and hypertrophy (Kärpänen et al. 2008; Koch and 
Claesson-Welsh 2012). 
The core receptors of Placental growth factor (PlGF) are VEGFR-1 and NRP-1 
(Maglione et al. 1991; Koch 2012). PlGF itself plays no crucial role in vascular 
formation during the embryogenesis (Gigante et al. 2003; Carmeliet and Jain 2011) 
but it is an important costimulator of VEGF effects (Park et al. 1994; Carmeliet et al. 
2001). Under certain circumstances, PlGF can promote cardiac hypertrophy 
(Accornero et al. 2011). 
VEGFR-1 (alternatively defined as fms-like tyrosine kinase, Flt-1) is a predominant 
receptor for VEGF-A, VEGF-B and PlGF (Carmeliet and Jain 2011; Koch 2012). Two 
forms of VEFGR-1 exist: the membrane-based VEGFR-1 and a soluble form 
(sVEGFR-1) (Kendall and Thomas 1993; Ambati et al. 2006; Giacca and Zacchigna 
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2012). Multiple cell types express VEGFR-1: endothelial cells, smooth muscle cells, 
monocytes, macrophages, and haematopoietic stem cells (Maglione et al. 1991; 
Couper et al. 1997; Gigante et al. 2003; Carmeliet and Jain 2011; Koch 2012). 
Depending on the site of VEGFR-1 expression, it can regulate angio- and 
arteriogenesis, myelomonocyte cell recruitment or even lipid metabolism (Luttun et 
al. 2002; Pipp et al. 2003; Kärpänen et al. 2008; Hagberg et al. 2010; Hagberg et al. 
2012 Sep 25). Deletion of VEGFR-1 leads to global vascular malformations and 
embryonic death (Fong et al. 1995; Fong et al. 1999). Important for the interplay of 
the receptors, VEGFR-1 has a high binding capacity to VEGF-A but a very low 
activity of tyrosine kinase, thus functioning as a negative regulator of VEGFR-2 in 
endothelial cells (Hiratsuka et al. 1998; Accornero et al. 2011).  
VEGFR-2 (alternatively defined as kinase-insert domain receptor, KDR or Flk-1) has 
predominant binding affinity to VEGF-A, and to lesser extent to VEGF-C and VEGF-
D. Embryonic haematopoiesis and vasculogenesis is highly dependent on VEGFR-2 
expression, whereas it is usually silent in healthy adults (Kaipainen et al. 1993; 
Shalaby et al. 1995). Vascular endothelial cells are the main expression site of 
VEGFR-2, which is thus crucial for the VEGF-A-related endothelial effects (Carmeliet 
and Jain 2011; Koch and Claesson-Welsh 2012). The sites of active angiogenesis 
during wound healing, myocardial infarction or malignancies are actively expressing 
VEGFR-2 (Shibuya 1994; Li et al. 1996). 
The simplified schematic overview suggests straight differentiation of VEGF ligands 
and receptors into either mainly angiogeneic or mainly lymphangiogenic. However, 
various cross-reactions are possible (Nagy et al. 2002). 
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4.1.2 Lymphangiogenic VEGF ligands and receptors 
VEGF-C is the main ligand involved into the development of lymphatic vascular 
system. VEGF-C demonstrates the highest binding affinity to its core receptor 
VEGFR-3, although also being affine to VEGFR-2 (Jeltsch et al. 1997; Oh et al. 
1997; K. Alitalo 2011; Kim et al. 2012). Accordingly, the predominant lymphatic 
effects of VEGF-C can be combined with angiogenic actions determined by VEGFR-
2 binding (Saaristo et al. 2002; Tammela et al. 2011; Benedito et al. 2012 Mar 18). 
The VEGF-C precursor protein requires proteolytic processing to transform to the 
active ligand form (Joukov et al. 1996; Kukk, Lymboussaki, Taira, Kaipainen, Jeltsch, 
Joukov, and Alitalo 1996b). Proinflammatory cytokines TNF-α, IL-1?α and IL-β induce 
the VEGF-C gene expression  (Ristimäki et al. 1998). Further, PlGF, epidermal 
growth factor and transforming growth factor-b have the ability to induce the VEGF-C 
secretion (Enholm et al. 1997). Importantly, inflammatory cells, antigen presenting 
cells and some subsets of T-lymphocytes are a rich source of VEGF-C (Schoppmann 
et al. 2002; Hamrah et al. 2003; Cursiefen et al. 2004; Baluk et al. 2005; Nykanen et 
al. 2010). 
VEGF-C is crucial for the development during the embryogenesis, thus loss of 
VEGF-C activity leads to embryonic death (Karkkainen et al. 2004). Therapeutic 
inhibition of VEGF-C-VEGFR-3 axis leads to suppression and degradation of existing 
lymphatics and ends in lymphedema (Makinen et al. 2001). The VEGF-C 
overexpression, on the other hand, leads to lymphatic hyperplasia (Jeltsch et al. 
1997; Oh et al. 1997). Due to the crucial role of lymphatic vascular system in the 
processes of inflammation, VEGF-C is induced in many malignancies and is very 
likely to play a role in lymphatic tumor metastasis (Mandriota et al. 2001; Skobe, 
Hawighorst, et al. 2001). 
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VEGF-C is not only directly involved into the process of lymphangiogenesis, but also 
affects the phenotype of lymphatic endothelial cell depending on the physiological or 
pathological condition. So, VEGF-C can turn lymphatics more attractive for tumor 
cells or antigen-presenting cells by secreting a chemokine CCL-21 (Issa et al. 2008; 
Nykanen et al. 2010). And as the core receptor of VEGF-C, VEGFR-3, can be 
expressed on the macrophages and dendritic cells, direct cellular effects of VEGF-C 
are described (Chen et al. 2004; Hajrasouliha et al. 2012). The divertive stimulating 
affinity of VEGF-C to both, lymphatic endothelial cells and inflammatory cells, that 
travel towards lymphatics, explains the important function of VEGF-C-VEGFR-3 
interaction in the regulation of various immune response reactions (Skobe, Hamberg, 
et al. 2001; Chen et al. 2004; Nykanen et al. 2010; Hajrasouliha et al. 2012). Thus, 
several processes can be orchestrated by lymphangiogenic factors: transportation of 
antigen-presenting cells, the initiation of immune responses, induced lymphatic 
drainage of the inflamed sites and the resolution of inflammation (Huggenberger et 
al. 2010; Huggenberger et al. 2011; Zhou et al. 2011). 
The second known lymphangiogenic ligand is VEGF-D, which also binds to VEGFR-
2 and VEGFR-3 (Baldwin et al. 2001). Importantly, VEGF-D is not crucial for the 
initial lymphangiogenesis (Baldwin et al. 2005). VEGF-D repeats in main functions 
and physiological roles the key roles of VEGF-C (Stacker et al. 2001; Byzova et al. 
2002; Rissanen et al. 2003). 
VEGFR-3 is the main lymphangiogenic receptor with the predominant binding affinity 
to its primary ligands VEGF-C and VEGF-D (Jeltsch et al. 1997; Karkkainen et al. 
2004). VEGFR-3 is a selective director of the lymphatic growth and lymphatic vessel 
maintenance, mainly being expressed on the lymphatic endothelial cells (Makinen et 
al. 2001). However, VEGFR-3 is also expressed in various inflammatory cells, mainly 
described for macrophages and dendritic cells (Hamrah et al. 2003; Chen et al. 2004; 
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Maruyama et al. 2005). The angiogenic effects of VEGFR-3 have also been well 
described and can be explained by VEGFR-3 expression in blood endothelial cells 
(Tammela et al. 2011; Benedito et al. 2012 Mar 18). Also VEFG-C binding to 
VEGFR-3 positive macrophages can lead to VEGF-A upregulation with consequent 
angiogenic cascade development (Chung et al. 2009). 
 
4.2 Lymphatic specific cardiac VEGF pathways 
4.2.1 in embryogenesis and in healthy adult heart 
The development of the vascular system and the heart in particular is a complex 
process of coordinated signalling pathways, where the vascular endothelial growth 
factors are central. The lymphatic system is taking its origin from the venous 
endothelial cells in the early embryogenesis, which transform to lymphatic endothelial 
cells upon binding with VEGF-C (Wigle and Oliver 1999; Karkkainen et al. 2004). 
These very initial LECs already express the whole spectrum f classical lymphatic 
receptors, such as PROX-1, VEGFR-3 and Podoplanin. Exposed to further VEGF-C 
signals, the processes of sprouting and migration of LECs result in the creation of 
lymphatic sacs (Karkkainen et al. 2004). The final formation of lymphatic capillaries 
requires the involvement of Notch signaling pathways, the VEGF-C co-receptor NRP-
2 and ligand ephrin B2 (Mäkinen et al. 2005; Xu et al. 2010; Niessen et al. 2011). 
Lymphatic specific receptor VEGFR-3 is inevitable during the early vascular 
development and becomes restricted to the regulation of lymphatic endothelial 
biology during the first 12 weeks (Dumont et al. 1998; Partanen et al. 1999). During 
the whole period of gestation, the lymphatic capillaries can only be detected in 
human fetal epicardium and besides VEGFR-3 positivity, these vessels demonstrate 
strong VEGFR-2 expression (Partanen et al. 1999). 
? 28 
Even less is currently known about the phenotype of adult cardiac lymphatics. The 
available reports on cardiac lymphatics in adult rats describe the predominant 
distribution of VEGFR-3 expressing capillaries mainly in the epicardium, whereas the 
myocardial area has less lymphatics (Nykanen et al. 2010). 
 
4.2.2 in heart failure 
The lymphatic endothelial biology in patients with terminal heart failure has never 
been studied sufficiently, although the details of endothelial changes in myocardial 
ischemia and infarction have been very well highlighted. However, the impact of 
lymphatic system in cardiac failure cannot be exaggerated, as the microvascular 
environment, hemodynamical conditions, fluid and metabolic balance are roughly 
impaired. Our current knowledge is only based on the spare reports of lymphatic 
signaling involvement in ischemic and dilative cadyomyopathy. For instance, VEGF-
C encoding is severely induced in patients with any aetiology of terminal heart failure 
(Aharinejad et al. 2001). Further, various vascular endothelial growth factors have a 
differential expression pattern in different forms of heart failure (Dashkevich, Bloch, et 
al. 2010). 
Obviously, further evidence of lymphatic role in heart failure is required to elaborate 
on potential therapeutic targets in this field. 
 
4.2.3 in heart transplantation (allorecognition and rejection) 
The development of alloimmune response after cardiac transplantation begins with 
the migration of antigen presenting cells from cardiac allograft to secondary lymphoid 
organs (Larsen et al. 1990; Lakkis et al. 2000). The afferent lymphatics provide the 
initial route for the APCs ´travel Thus, the allograft lymphatics are important in the 
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initiation of allorecognition. 
Recently, a detailed description of cardiac lymphatic changes in myocardial rejection 
has been provided (Nykanen et al. 2010). Interestingly, experimental acute and 
chronic rejection episodes lead to controversial changes of lymphatic vessel density, 
which significantly drops in acute rejection and is doubled in chronic rejection. These 
changes of lymphatic density seem to represent their secondary reaction on various 
inflammatory processes associated with allograft rejection. Importantly, the role of 
cardiac lymphatics in the setting of transplantation is definitely much wider, as they 
seem to be crucial in the initiation of alloimmune cascade.  
So, experimental therapeutic VEGFR-3 blocking in cardiac allograft recipients has 
reduced allograft inflammation and the development of chronic allograft vasculopathy 
(Nykanen et al. 2010). 
The early involvement of lymphatic endothelial cells and lymphagiogenesis in the 
initial processes of allograft rejection seemed of high relevance to me and have 
therefore been chosen as the central focus of the experimental part of the presented 
work. 
 
The members of the VEGF family seem to be intimately involved in the normal 
healthy development of cardiac vascular and lymphatic systems. They further 
represent important functional units in the pathogenesis of various cardiac diseases. 
As many of them are beyond the scope of this review, a short overview of lymphatic 
specific VEGF expression and signaling in cardiac disease are presented in Figure 
5. 
It was the principle aim of the performed work to broaden the understanding of 
lymphatic signaling mechanisms in failing hearts and after heart transplantation and 
to possibly highlight potential therapeutic approaches. 
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Figure 5. Brief overview of cardiac lymphatic VEGF expression and signaling in 
healthy and diseased heart. Figure authored by Alexey Dashkevich, copyright by 
John Wiley and Sons; reprinted with permission. 
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4.3 Lymphatic specific VEGF pathways in the lung 
4.3.1 in embryogenesis and in healthy adult lungs 
During the pulmonary growth, vascular endothelial growth factors are actively 
participating in vasculo- and lymphangioenesis. VEGF-C and its receptor VEGFR-3 
are in particular also expressed here during embryogenesis (Kukk, Lymboussaki, 
Taira, Kaipainen, Jeltsch, Joukov, and Alitalo 1996a). In mouse lungs, VEGF-D 
cannot be found during the early phase but is later on expressed in the mesenchymal 
tissue of the lungs, disappearing again after the birth (Greenberg et al. 2002). 
The classical angiogenic growth factor VEGF-A has also been shown to overtake a 
certain role in lymphangiogenesis of developing lungs, as its overstimulation leads to 
increased lymphatic density in foetus. This lymphangiogenic switch of VEGF-A might 
be explained by it cross-reaction with VEGFR-3 (Mallory et al. 2006). Further, VEGF-
A is important for maturation and alveolarization of the developing lung (Lassus et al. 
1999). 
Generally, the detailed role of lymphatic endothelium in healthy lungs is still not 
clearly understood, with only fragmental pieces of evidence found in the literature. 
For instance, VEGF-C is detectable in tracheal fluid samples of the new-born, being 
present in the bronchial epithelium. Reduced level of the lymphangiogenic ligand is 
associated with underdevelopment of pulmonary lymphatic system and subsequent 
lung edema, as described in prematurely born. Prenatal injection of corticosteroids 
increase VEGF-C levels, which may promote the maturation process (Janér et al. 
2006). 
 
4.3.2 in lung transplantation 
Lung transplantation is very similar to cardiac transplantation in terms of 
? 32 
transplantation immunology. Thus, lymphatic system might also play an important 
role in the initiation of alloimmune responses after clinical lung transplantation. 
However, even less data than for cardiac transplantation are currently available for 
the lungs. 
The inevitable cold preservation of the lung allograft leads to pulmonary edema, 
which is associated with increased levels of VEGF-a and VEGF-C (ABRAHAM et al. 
2002). These changes may be the initiation point of later BOS development. In 
pathogenesis of BOS, VEGF-A is also likely to show lymphangiogeneic cross-
reaction, stimulating lymphatic growth, thus inducing the alloimmune responses 
(Krebs et al. 2005). 
In human lung transplant recipients, the pathogenetic relevance of vascular 
endothelial growth factors has been proven to be evident, especially for the 
development of BOS (Luckraz et al. 2004; Belperio et al. 2005; Dutly et al. 2005; 
Langenbach et al. 2005). However, there are are currently almost no data on the 
pathogenetic role of lymphangiogenesis and lymphangiogenic factors in lung 
transplantation, although they appear relevant. For instance, total body lymphoid 
irradiation is beneficial for the prevention of primary lung dysfunction in lung allograft 
recipients (Fisher et al. 2005). 
 
In summary, lymphangiogenic and angiogenic growth factors are evidently relevant 
for the development of healthy heart and lung, as well as for pathogenesis of various 
cardiac and pulmonary diseases. And although the current body of evidence appears 
to be very limited, available data can give the direction for the elaboration of 
potentially valid therapeutic approaches in the future. Obviously, this field still 
warrants further research, as various questions have not been answered yet. 
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AIMS OF THE STUDY 
The initial aims of presented work were: 
 
• to investigate the changes of lymphatic endothelial phenotype in patients with 
terminal heart failure 
 
• to investigate the changes of lymphatic endothelial phenotype during the 
postoperative course after heart and lung transplantation in human patients 
 
• to prove the link of allograft rejection after heart and lung transplantation with 
the phenotype and function of lymphatic endothelium 
 
• to reveal exact mechanistic role of lymphatic endothelium in acute allograft 
rejection and to clarify the cause-effect relation between allograft rejection and 
lymphatic endothelium 
 
• to reveal the role of ischemia-reperfusion injury in the functioning of the 
allograft lymphatic endothelial cells 
 
• to test VEGFR3 inhibiting strategies as an alternative and clinically feasible 
immunomodulatory approach targeting lymphatic vessels 
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METHODS 
In the study, the functional parameters and biopsies from the human patients who 
underwent heart or lung transplantation were analysed. Further, experimental studies 
using heterotopic abdominal heart transplantation model in rat and mouse were 
applied. 
 
1 Patients with end-stage heart failure 
All procedures were fully approved by the ethics committee of the medical faculty of 
the University of Cologne and followed the Declaration of Helsinki guidelines. 
Transmural left ventricular endomyocardial biopsies taken from recipient hearts 
group failing heart) immediately after explantation of the organ, and from donor 
hearts (control) taken during organ harvest, immediately after aortic cross-clamp, 
were investigated. 
The biopsies of the patients were analysed in the retrospective manner. The 
demographic data of the included patients are represented in the Table 2. 
 
Table 2. Demographic characteristics of the study cohort, paper I. 
 Terminal heart failure Control (donor hearts) 
n 7 
Dilative cardiomyopathy (n=5) 
Ischemic cardiomyopathy (n=1) 
Vasculitis (n=1) 
8 
sex 7 males 7 males, 1 female 
age 57,1 ± 3,4 38,1 ± 11,0 
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2 Heart transplant patients 
All heart transplantations were performed in the department of cardiothoracic 
surgery, University of Cologne, Germany. All procedures were approved by the 
University of Cologne Medical Faculty Ethics Committee and followed the Declaration 
of Helsinki guidelines. 
The biopsies of the patients were analysed in the prospective manner. The 
demographic data of the included patients are represented in the Table 3. The 
indication for HTX was terminal heart failure due to dilative cardiomyopathy in eight 
patients, ischemic cardiomyopathy in 17 patients, and congenital heart disease in 
one patient. All transplantations were performed with bicaval anastomosis. 
 
Table 3. Demographic characteristics of the study cohort, paper II. 
 Heart transplant recipients Heart donors 
n 26 26 
sex 21 males 17 males 
age 55.8 ± 9 years (20—68 years) 35.8 ± 12.4 years (17—59 years) 
 
Myocardial biopsies 
In order to investigate a possible link between histologically verified rejection and 
lymphatic endothelial marker density, the biopsies from patients with no rejection 
episode during the first 12 months after HTX (n = 17) were compared to biopsies 
from patients with at least one rejection of ISHLT grade IIIa or higher (n = 9). 
Right ventricular endomyocardial biopsies from 26 heart transplant recipients, taken 
for routine rejection monitoring during the first 12 months after HTX, were used for 
analysis. For the study, the following time points were investigated: 0.5, 1, 1.5, 6, and 
12 months after HTX. 
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3 Lung transplant patients 
All lung transplantations were performed in the departments of cardiovascular and 
thoracic surgery of Freiburg University Medical Centre, Freiburg, Germany. All 
procedures were approved by the Ethics Committee of Freiburg University Medical 
Centre and followed the Declaration of Helsinki guidelines. Written informed consent 
was obtained from all patients. 23 lung transplant recipients underwent routine 
rejection monitoring at 14 days and at 90 days after LTX by transbronchial biopsy. 
The indication for LTX was cystic fibrosis in 12 patients, chronic obstructive 
pulmonary disease in 7 patients, emphysema in 2 patients, bronchoalveolar 
carcinoma in 1 patient, and bronchiolitis obliterans in 1 patient. The demographic 
data of the included patients are represented in the Table 4. In 19 patients with 
double LTX, surgery was performed as sequential single LTX; 4 patients received a 
single lung. 
 
Table 4. Demographic characteristics of the study cohort, paper III. 
 Lung transplant recipients Lung donors 
n 23 23 
sex 14 males 11 males 
age 47 ± 15 years (17 – 65 years) 32.0 ± 13.2 years (16—67 years) 
 
Primary Graft Dysfunction 
Primary graft dysfunction (PGD) was defined as a severe radiological infiltrate in 
association with a PaO2:FiO2 ratio less than 200 during the first 48 hours after 
transplantation. 
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Spirometric Analysis 
Spirometry was performed for routine clinical monitoring in every patient with an 830-
L whole-body plethysmograph (Masterlab Jaeger, Wurzburg, Germany). The results 
of spirometric measurements 14 and 90 days after LTX (the same day as 
transbronchial biopsies) were recorded. The following lung function indices were 
obtained: inspiratory vital capacity (IVC [L]), forced expiratory volume in 1 second 
(FEV1 [L]), and forced midexpiratory flow rate at 25% to 75% of forced vital capacity 
(FEF75/25 [L/s]). The FEF75/25 at chosen time-points was set in relation with the 
measurements during the first year after LTX. A reduction of FEF75/25 compared 
with the best postoperative value was considered to represent the clinical 
manifestation of BOS. Spirometric analysis in every patient allowed the strict 
differentiation between BOS and acute allograft rejection in the examined patients. 
Lung Biopsies 
Transbronchial lung biopsies, taken during routine rejection monitoring, were used for 
analysis. For the study, the time points 14 and 90 days after LTX were investigated. 
Samples from patients with histologically verified pneumonia were excluded from 
further analysis. 
 
4 Heart transplantation model in rat and mouse 
The State Provincial Office of Southern Finland approved all animal experiments. 
The animals received care in compliance with the Guide for the Care and Use of 
Laboratory Animals as outlined by the National Academy of Sciences (ISBN 0-309-
05377, revised 1996). For anaesthesia and perioperative analgesia, the recipient rats 
and mice inhaled isoflurane (Isofluran, Baxter, Deerfield, IL) and received s.c. 
buprenorphine (Temgesic, Schering-Plough, Kenilworth, NJ). Each group had 5 to 10 
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animals. 
The heterotopic cardiac transplantations were performed in full-mismatched major 
histocompatibilty rat and mouse cardiac allograft models. The donor hearts were 
perfused with ice-cold heparinized phosphate-buffered saline (PBS), and excised. 
The donor heart was preserved at +4°C PBS for 4 h (Tuuminen et al. 2011). The 
operation time (time of warm ischemia) was standardized to 1 h. 
Heterotopic heart transplantation in rat 
After preservation, heterotopic cardiac transplantations were performed between fully 
MHC-mismatched, pathogen-free, inbred 8- to 12-week-old male DA donor and 
Wistar Furth (WF, RT1u) recipient rats (Harlan Laboratories, Boxmeer, The 
Netherlands). Syngeneic heart transplantations were performed between DA rats. 
After reperfusion, the recipients were sacrificed at 6 h to analyse lymphatic 
endothelial activation with immunofluorescence, inflammatory cell influx with 
immunohistochemistry, phenotype and proportions of antigen-presenting cells by flow 
cytometry, myocardial injury with serum troponin T (TnT) analysis, and innate 
immune activation with real-time quantitative reverse-transcription PCR. 
At 10 d after reperfusion, adaptive immune response activation was analysed with 
real-time quantitative reverse-transcription PCR and the inflammatory cell influx with 
immunohistochemistry. At 8 weeks, the degree of cardiac fibrosis and allograft 
vasculopathy was assessed with histological stainings. 
To determine the effect of donor treatment with VEGF-C/D trap on allograft survival, 
recipients received low dose immunosuppression of cyclosporine A 1 mg/kg/d s.c. 
until the deterioration of graft function, assessed by palpation. 
Heterotopic heart transplantation in mouse 
Inbred male BALB/c (B/c, H-2d) and C57BL/6J (B6, H-2b) mice (Harlan Laboratories, 
Boxmeer, The Netherlands) 2-3 months of age were used for heterotopic heart 
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transplantation model in mouse. In the mouse model, allografts were harvested at 5 
days after reperfusion to analyse the inflammatory cell influx and the activation of 
alloimmune response. To determine the effect of donor treatment with VEGFR-3 
antibody on allograft survival, recipients received low dose immunosuppression of 
FK506 (Astellas, Tokyo, Japan) 1.5 mg/kg/d s.c. until the deterioration of graft 
function, assessed by palpation. 
Medication 
The coronary arteries of the donor rat hearts (Dark Agouti; DA, RT1av1) were 
perfused with 200 µl of mutant VEGF-C (1 μg/ml, in PBS), VEGF-C/D trap (10 μg/ml, 
in PBS) or with PBS. 
Allograft donors (BALB/c) were treated intraperitoneally with 800 μg rat anti-mouse 
VEGFR-3 neutralizing antibody (mF4-31C1; ImClone, New York, NY) or 800 μg rat 
IgG (Sigma-Aldrich, St. Louise, MO). 
In the rat heart transplantation model, to prevent irreversible episodes of acute 
allograft rejection, to achieve long-term allograft survival, and to enable the 
development of chronic rejection, the recipients in the 10-d and 8-week groups 
received s.c. Cyclosporine A (Novartis, Basel, Switzerland) 2 mg/kg/day for the first 7 
days and 1 mg/kg/day thereafter. 
VEGF-C/D trap 
VEGF-C was inhibited using a protein chimera of VEGFR-3 (soluble VEGFR-3(D1-
3)-Fc fusion protein), which was produced in a baculovirus Drosophila S2 system. 
The protein is capable to bind full-length, processed and mature forms of VEGF-C 
and D in human, rat and mouse. The soluble VEGFR-3(D1-3)-Fc fusion protein was 
produced and purified as previously described (Anisimov et al. 2009). 
Vegfr3iΔLEC mice 
To dissect whether LECs are mechanistically responsible for the beneficial effects of 
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VEGFR3 inhibition on allograft rejection, we constructed C57BL/6J mice with 
conditionally knocked out VEGFR3 in LECs (Vegfr3iΔLEC), and used them as cardiac 
allograft donors in acute allograft survival study. Prox1iCreERT2;Vegfr3flox/flox 
(Vegfr3iΔLEC) and Vegfr3flox/flox  control mice were treated with intraperitoneal injections 
of tamoxifen for 3 consecutive days. Ten days after the last injection the mice were 
anesthetized and their hearts were used for transplantation. 
 
5 Immunohistochemistry and immunofluorecence stainings 
Cryostat sections were stained for subsets of inflammatory cells and blood and 
lymphatic microvascular vessels using the peroxidase ABC method (Vectastain Elite 
ABC Kit, Vector Laboratories) and the reaction was developed with 3-amino-9-
ethylcarbazole (AEC, Vectastain). Immunofluorescent stainings were performed 
using Alexa 564 red and Alexa 488 green (Promega, Madison, WI) secondary 
antibodies. We used the following antibodies and dilutions: VEGFR-3 (10 μg/ml, 
AF743, R&D Systems, Minneapolis, MN), VCAM-1 (10 μg/ml, MMS-141P, Covance, 
Princeton, NJ); ICAM-1 (10 μg/ml, 1A29, Seikagaku, Tokyo, Japan), rabbit anti-
human LYVE-1 (1 μg/ml, Molecular Cancer Biology Laboratory, Helsinki), RECA-1 for 
rat endothelium corresponding to human CD31 (50 μg/ml, MCA97, AbD Serotec, 
Dusseldorf, Germany); CD4 for T cells (5 µg/ml; anti-rat 22021D and anti-mouse 
553043, BD Pharmingen, San Diego, CA), CD8 for T cells (5 µg/ml; anti-rat 22071D 
and anti-mouse 553027, BD Pharmingen), ED1 for macrophages (5 µg/ml, 22451D, 
BD Pharmingen, San Diego, CA); CD11b (553308) and CD11c (553799) for 
mononuclear cells in mouse (BD Pharmingen, San Diego, CA); MPO for neutrophils 
(20 µg/ml, ab9535, Abcam, Cambridge, UK); OX62 for dendritic cells (10 µg/ml, MCA 
1029G, Serotec, Oxford, UK); OX76 for DA-specific MHC Class II RT1Ba/c molecule 
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(10 µg/ml, MCA826, AbD Serotec, Düsseldorf, Germany). The immunoreactivity was 
quantified in a blinded manner using 400x magnification. 
 
6 Acute myocardial injury 
Myocardial troponin T (TnT) levels in serum samples, derived at 6 h after reperfusion, 
determined acute myocardial injury. We analysed TnT with the fifth generation TnT 
test (Troponin T STAT, Roche Diagnostics, Mannheim, Germany), which shows 
cross-reactivity of 0.001 % with TnT originating in skeletal muscle at a concentration 
of 2.000 ng/ml. The functional sensitivity is 0.05 µg/l and the lower detection limit 
0.01 µg/l. The TnT was measured by electrochemiluminescence immunoassay 
(ECLIA) with the Elecsys 2010 immunoassay analyser (Roche Diagnostics). 
 
7 Flow Cytometry 
Isolation and preparation of myocyte-depleted cardiac cells 
Cardiomyocyte-depleted mononuclear cell suspensions were prepared as previously 
described (Pfister et al. 2005) with modifications. Briefly, the cardiac tissue was 
minced and digested in the enzymatic solution, consisting of 10mg/mL collagenase 
IV (Gibco BrL, New York, NY), 2.4 U/mL dispase II (Roche Molecular Biochemicals, 
Mannheim, Germany), 1mg/mL DNase I (Sigma-Aldrich, St. Louise, MO) and 2.5 
mmol/L CaCl2 at 37°C for 60 minutes. The cell suspensions were then filtered 
through 70µm mash, and washed with Hanks’ balanced salt solution (HBSS) buffer. 
Cell surface antigen staining was performed using fluorochrome-conjugated 
monoclonal mouse anti-rat antibodies CD45-V450 (BD Pharmingen, San Diego, CA), 
CD103-PE (OX62, eBioscience, San Diego, CA), CD68-Alexa700 (ED1), OX76-
FITC, CCR7-PE/Cy7 and CD86-Alexa647 (all AbD Serotec, Düsseldorf, Germany) 
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and VEGFR3-Alexa488 (Bioss, Woburn, MA) at 4°C for 15 minutes. Respective 
isotype controls were used as negative controls. 
FACS analysis 
FACS was performed using BD FACSAria Iiu (BD Biosciences, San Diego, CA) 
equipped with three lasers (blue 488 nm, red 633 nm and violet 407 nm). Acquired 
data were analysed using BD FACSDiva™ software 6.1 (BD Biosciences, San 
Diego, CA). 
 
8 RNA isolation and quantitative RT-PCR 
We isolated total RNA from tissue samples, dissected from the myocardial apex of 
the allografts, using RNeasy kit according to the Manufacturer’s instructions (Qiagen, 
Hilden, Germany) and reverse transcribed the RNA by using the High-RNA-to-cDNA 
kit (Applied Biosystems, Foster City, CA). We performed quantitative real-time PCR 
on a RotorGene-6000 (Corbett Research, Doncaster, Australia) using 2X DyNAmo 
Flash SYBR Green Master mix (Finnzymes, Espoo, Finland) and measured the 
mRNA quantities of the following factors from each group: lymphangiogenic factors 
VEGF-C, VEGFR-3, PROX-1, chemokines CXCL-2, CXCL-5, CCL-20, CCL-21, 
CINC-1, innate immune receptors TLR2 and TLR4, their ligands HAS1-3, HMGB1, 
transcription factor NF-kappa B subunits p50, p52, p65, dendritic cell maturation 
markers CD40, CD80, CD86, CD83, CCR7 and CCR8, as well as inflammatory 
cytokines interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12p35, IL-17A, tumor necrosis 
factor (TNF)-α, interferon (IFN)-γ, IP-10, transforming growth factor (TGF)-β. The 
number of mRNA copies of the gene of interest was calculated from a corresponding 
standard curve using the RotorGene software. Of the tested housekeeping genes 
(18SRNA, GAPDH, b-actin and TBP), 18SRNA was most stably expressed (data not 
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shown) and therefore all RT-PCR data were normalized against 18SRNA. Table 5 
provides GenBank access numbers for each primer. 
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Table 5. GenBank access numbers for PCR-analyzed genes. 
 
GENE  Primers with appropriate GenBank # 
 
VEGF-C  NM_053653 
fwd  5'-CCCTGAATCCTGGAAAATGTGC-3' 
rev  5'-TCAAGGCAGCAAAATGATGGAC-3' 
 
VEGFR-3 NM_053652 
fwd  5'-CTGGCTGCTCGGAACATTTTAC-3' 
rev  5'-ATCAAAGATGCTCTCGGGGG-3' 
 
PROX-1  NM_001107201 
fwd  5'-CAATGATGGAGTCACCAGCACAG-3' 
rev  5'-GGAGTTCTTGTAGGCAGTTAGGGG-3' 
 
CXCL1  NM_030845 
fwd   5'-CAAACCGAAGTCATAGCCACACTC-3' 
rev  5'-TTGTCAGAAGCCAGCGTTCAC-3' 
 
CXCL2  NM_053647 
fwd  5'-CAATGCCTGACGACCCTACCA-3' 
rev  5'-GTTTCTTTTCTCTTTGATTCTGCCC-3' 
 
CXCL-5  NM_022214 
fwd  5'-GCTCCGTTGATAAAGAAAGTCATTCAG-3' 
rev  5'-GGCTGATCTGACCAGTGCAAGTG 
 
CCL19  NM_001108661 
fwd  5'-TCAGGCTCATTCATTCTCTGTGG-3' 
rev  5'-CAGCAGTCTTCCGCATCGTTAG-3' 
 
CCL20  NM_019233 
fwd  5'-GCAACTTTGACTGCTGCCTCAC-3' 
rev  5'-GCATCCGTTTTTACATCTTCTTGG-3' 
 
CCL21  NM_001008513 
fwd  5'-CATCCCAGCAATCCTGTTCG-3' 
rev  5'-CTTTCTTCCCAGACTTAGAGGTTCC-3' 
 
TLR2  NM_198769 
fwd  5'-GAGGTCTCCAGGTCAAATCTCAGA-3' 
rev  5'-ACACACACCAGCAGCATCACAT-3' 
 
TLR4  NM_019178 
fwd  5'-GCATTGTTCCTTTCCTGCCTG-3' 
rev  5'-AAATCCAGCCACTGAAGTTGTGAG-3' 
 
HAS1  NM_172323 
fwd  5'-TACACGGCTTTCAAGGCACTGG-3' 
rev  5'-ACATCTCCTCCAACAGCACCTACC-3' 
 
HAS2  NM_013153 
fwd  5'-ACTGGGCAGAAGCGTGGATTATGT-3' 
rev  5'-AACACCTCCAACCATCGGGTCTTCTT-3' 
 
HAS3  NM_172319 
fwd  5'-CCCTTGGCAACTCAGTGGACTAC-3' 
rev  5'-AGACCCGAAGCATCTCAATGG-3' 
 
HMGB1  NM_012963 
fwd  5'-TGCTCAGAGAGGTGGAAGACCAT-3' 
rev  5'-GGGGGGGATGTAGGTTTTCATT-3' 
 
NFκB p50 L26267 
fwd  5'-CTACACTTAGCCATCATCCACCTTC-3' 
rev  5'-CTCCACCACATCTTCCTGCTTG-3' 
 
NFκB p65 NM_199267 
fwd  5'-AGGACCTACGAGACCTTCAAGAGC-3' 
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rev  5'-TGATGGTGCTGAGGGATGTTG-3' 
 
CD40  NM_134360 
fwd  5'-TGATACTGTCTGCCAACCCTGC-3' 
rev  5'-TCTGACTTGTTCCTTCCCGTAGG-3' 
 
CD80  NM_012926 
fwd  5'-TGCTGCTGGTTGGTCTTTTCC-3' 
rev  5'-CGGTGTATGGACTGCTCTTCAGAAC-3' 
 
CD86  NM_020081 
fwd  5'-TTGGGAATCCTTTTCTCGGTG-3' 
rev  5'-TTTGAGCCTTTGTGAACGGG-3' 
 
CD83  NM_001108410 
fwd  5'-GCCTTATTCCTTGACAATCCAAAAC-3' 
rev  5'-GACCAGAGAGAAGAGCAACACAGC-3' 
 
CCR7  NM_199489 
fwd  5'-TGGCTCTCCTGGTCATTTTCC-3' 
rev  5'-CTTGAAGCACACCGACTCATACAG-3' 
 
CCR8  XM236704 
fwd  5'-GCAAGAAACTGAGGAGTATCACGG-3' 
rev  5'-CAGCAGGTTGTGGGTCTGAAAG-3' 
 
IL-1β  NM_031512 
fwd  5'-GCTATGGCAACTGTCCCTGAACTC-3' 
rev  5'-CGAGATGCTGCTGTGAGATTTGAAG-3' 
 
IL-2  NM_053836 
fwd  5'-GCAGCGTGTGTTGGATTTGACTC-3' 
rev  5'-GAGATGATGCTTTGACAGATGGC-3' 
 
IL-4  NM_201270 
fwd  5'-GCAACAAGGAACACCACGGAGA-3' 
rev  5'-CCCTCGTAGGATGCTTTTTAGGC-3' 
 
IL-6  NM_012589 
fwd  5'-TTGTTGACAGCCACTGCCTTC-3' 
rev  5'-GAATTGCCATTGCACAACTCTTTTC-3' 
 
IL-10  NM_012854 
fwd  5'-ACCCACTTCCCAGTCAGCCA-3' 
rev  5'-TGCCTTGCTTTTATTCTCACAGG-3' 
 
IL-12p35  NM_053390 
fwd  5'-CCTTGGTAGCATCTATGAGGACTTG-3' 
rev  5'-CGCCGCTGTGATTCAGAGAC-3' 
 
IL-17A  NM_001106897 
fwd  5'-CTCAAAGTTCAGTGTGTCCAAACG-3' 
rev  5'-TCTATCAGGGTCCTCATTGCGG-3' 
 
TNF-α  NM_012675 
fwd  5'-TCTTCTGTCTACTGAACTTCGGGG-3' 
rev  5'-TCCTCTGCTTGGTGGTTTGC-3' 
 
IFN-γ  NM_138880 
fwd  5'-GCCATCAGCAACAACATAAGTGTC-3' 
rev  5'-AGAATCAGCACCGACTCCTTTTC-3' 
 
IP-10  RNU22520 
fwd  5'-TGAGCCAAAGAAGGTCTAAAAGAGC-3' 
rev  5'-AGCCGCACACTGGGTAAAGG-3' 
 
TGF-β  NM_021578 
fwd  5'-TGCTAATGGTGGACCGCAAC-3' 
rev  5'-CACTGCTTCCCGAATGTCTGAC-3'?
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9 Histology 
We used paraformaldehyde-fixed paraffin mid-cardiac cross-sections for histological 
stainings. We determined the degree of cardiac fibrosis from cross sections 
subjected to Masson’s trichrome staining and computer-assisted image processing 
(Zeiss Axiovision 4.4, Munich, Germany) by measuring the average proportional area 
stained for fibrosis from photographs captured with 100x magnification. We evaluated 
cardiac allograft vasculopathy from cross sections stained with hematoxylin-eosin, 
and Resorcin-Fuchsin for internal elastic lamina, by measuring the area between the 
internal elastic lamina and vessel lumen. The ratio of neointimal area to internal 
elastic lamina determined the arterial occlusion percentage. 
 
10 Statistics 
Data are presented by Kaplan-Meier survival plot or by box plots showing the upper 
extreme (excluding outliers), upper quartile, median, lower quartile, and lower 
extreme (excluding outliers), and the outliers are shown as circles outside the box. 
The data are analysed by Student t-Test or Mann-Whitney U test using PASW 
Statistics 19.0 (SPSS Inc., Chicago, IL). Log-rank analysis was used to evaluate 
allograft survival. P<0.05 was considered statistically significant. 
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RESULTS 
1 The phenotype of lymphatic endothelium is modified in terminal heart 
failure 
End-stage cardiac insufficiency is often associated with chronic myocardial edema. 
Increased myocardial lymph flow can be of specific pathophysiological importance in 
this situation. Thus, the aim of the study was to analyse the morphological and 
quantitative characteristics of the initial myocardial lymphatics in patients with 
terminal heart failure. 
The density and the ration of lumen presenting VEGFR-3+, LYVE+ and PROX-1+ 
vessels were determined in failing and control hearts. Figure 6 represents typical 
microscopic morphology of the open and collapsed lymphatic vessels. 
 
 
Figure 6. VEGFR3 positive lymphatics in left ventricular myocardium with typical 
morphology for an “open” (A) and collapsed (B) lymphatic vessel. 
 
A significantly higher ratio of LYVE-1+ open vessels was revealed in failing hearts, 
indicating possibly the modified functionality of the challenged draining system of 
oedematous cardiac tissue. In summary, the initial myocardial lymphatics undergo 
significant changes in patients with terminal heart failure. 
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2 The phenotype of myocardial lymphatic endothelium is modiefied after 
heart transplantation in humans 
In solid organ transplantation, the lymphatics have been shown to participate in the 
transfer of alloantigens to secondary lymphoid organs, initiating alloimmune 
responses (Larsen et al. 1990; Lakkis et al. 2000). Thus, the purpose of the Paper II 
was to analyse the myocardial lymphatic endothelial cell phenotype during the first 
year after heart transplantation in humans. The further goal was to find a possible 
association of lymphatic phenotype with rejection episodes. 
Our data demonstrated a significant decrease in the density of myocardial lymphatics 
(LYVE-1+ and PROX-1+ vessels) during the first year after cardiac transplantation. 
VEGFR-3+ vessels remained unchanged in their density (Figure 7). Further, multiple 
fluorescent stainings for VEGFR-3, LYVE-1, and PROX-1 demonstrated the 
accidence of VEGFR-3+ vessels that were negative for LYVE-1 and PROX-1 and 
were thus interpreted to be blood capillaries.  
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Figure 7. Densities of VEGFR-3+, LYVE-1+, and PROX-1+ capillaries during the first 
year after cardiac transplantation. The densities of positively marked capillaries were 
manually evaluated in myocardial cross-sections by immunohistochemistry. *p < 0.05 
and **p < 0.01 using t-Test. 
 
Patients with no significant rejection episodes during the first postoperative year 
showed a significantly higher density of VEGFR-3+ vessels two weeks after 
transplantation compared to the patients with at least one episode of significant acute 
rejection during the same time period. 
The results of the paper II for the first time described the change of lymphatic 
endothelial phenotype over time after heart transplantation in human patients and 
demonstrated a significant link between the episodes of acute allograft rejection and 
change in lymphatic phenotype. 
 
3 Acute allograft rejection after lung transplantation in humans is 
associated with upregulation of prolymphangiogenic factor PROX-1. 
The paper III investigated the relation between the verified acute rejection episodes 
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and lymphatic endothelial cell phenotype early after lung transplantation in humans. 
The density of PROX-1+ vessels was 22.7 ± 14.9 vessels mm-2 14 days after LTX, 
and that of VEGFR-1 and -2 were 14.5 ± 11.5 and 12.9 ± 7.1, respectively. No 
significant change of the marker densities between 2 weeks and 3 months after LTX 
was found. Further, biopsies from patients with significant acute rejection episodes 
showed a significantly higher density of PROX-1+ lymphatics, compared with patients 
who had no rejection, p < 0,001. For VEGFR-1 and VEGFR-2, no similar trend could 
be found (Table 6). 
This study was the first to demonstrate a link between a verified acute allograft 
rejection and lymphatic density after lung transplantation in human patients. 
 
Table 6. Vessel densities in patients with histologically evident acute rejection and 
patients with no rejection 
 Acute rejection 
(n=27) 
No rejection 
(n=19) 
p-value 
PROX-1 12.8 - 10.43 35.0 - 16.8 0.001 
VEGFR-1 17.2 - 10.6 13.0 - 8.3 0.78 
VEGFR-2 13.8 - 7.7 15.0 - 8.1 1.0 
 
4 VEGF-C-VEGFR-3 signaling in IRI is linked to acute lymphatic 
endothelial activation. 
The allograft harvesting and organ transportation time leads in clinical setting to 
inevitable tissue damage due to cold ischemic preservation and further ischemia-
reperfusion injury in the acute phase after the transplantation. Importantly, these 
processes are taking place in the allogeneic environment. It is unclear how this 
damage-associated cascade affects the lymphatic activation and consequent 
leukocyte trafficking and antigen presentation. Therefore, the goal of the paper IV 
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was to investigate the impact of organ preservation and IRI on the lymphatic vessel 
activation and the initiation of alloimmunity in rat cardiac allografts. According to our 
results, IRI induced the activation of lymphatic endothelial cells in rat cardiac 
allografts and had direct consequences for the development of alloimmune 
responses. 
We demonstrated that not the cold ischemic preservation per se, but reperfusion 
injury induced acute lymphatic vessel activation in rat cardiac allografts subjected to 
4 h cold ischemic preservation. We found that 4 h cold ischemic preservation 
significantly increased the level of VEGFR-3, ICAM-1 and VCAM-1 expression in 
LYVE-1 positive lymphatics during IRI, when compared to allografts subjected to 0 h 
ischemia. Real-time reverse-transcription polymerase chain reaction analysis showed 
that 4 h cold ischemia significantly increased VEGFR-3 and VEGF-C, as well as 
CXCL-2 mRNA levels during reperfusion. 
On the molecular level, we showed the importance of VEGF-C – VEGFR-3 signaling 
for IRI-related lymphatic activation. Even without 4 h cold ischemic preservation 
intracoronary ex-vivo perfusion of the allograft with mutant VEGF-C induced 
lymphatic vessel activation and increased mRNA expression of CCL-20, CCL-21 and 
CXCL-2. 
In summary, our results could show that specific VEGFR-3 stimulation induced 
lymphatic vessel activation in the allograft without prolonged cold ischemia, which is 
similar with the lymphatic activation in the setting of 4h cold graft ischemia. However, 
mutant VEGF-C treatment did not enhance lymphatic vessel activation nor mRNA 
levels of VEGFR-3 or any lymphatic related cytokines in cardiac allografts, subjected 
to 4h of cold ischemia. 
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5 VEGF-C/D inhibition prolonged allograft survival and prevented chronic 
rejection by regulating dendritic cell and lymphatic endothelial cell 
activation 
Our next goal was to prove the role of VEGF-C in the lymphatic vessel activation, 
which was associated with IRI. For this purpose we used a synthetic chimera of 
VEGFR-3 as a trap of autologous VEGF-C, given in the one single dosis 
intracoronarily immediately after allograft harvesting. We found that VEGFR3-trap 
significantly reduced the expression of VEGFR-3, ICAM-1 and VCAM-1 expression in 
LYVE-1+ lymphatics of rat cardiac allografts subjected to 4 h cold ischemia at 6h 
after transplantation, when compared to nontreated controls. However, the analysis 
by immunohistochemistry and flow cytometry demonstrated a significantly higher 
density of OX62+ dendritic cells in the VEGF-C/D trap treatment group, when 
compared to nontreated cardiac allografts. 
Moreover, treatment with VEGFR3 trap significantly reduced the level of CCR7 
expression on OX-62+ dendritic cells in the allograft. Thus, our results have 
demonstrated a central role for VEGF-C signaling in lymphatic vessel activation and 
dendritic cell maturation in cardiac allografts during ischemia-reperfusion injury. 
In chronically rejecting rat cardiac allografts, treatment with VEGFR3 trap was also 
linked with prolonged graft survival and decreased cardiac fibrosis and allograft 
vasculopathy (Figure 8). 
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Figure 8. Ex vivo intracoronary treatment with a single dose of VEGF-C/D trap 
prolongs cardiac allograft survival and prevents the development of cardiac 
fibrosis and allograft vasculopathy in rat cardiac allografts. The coronaries of 
DA donor hearts were ex vivo perfused with a one single dose of VEGF-C/D trap, or 
PBS. The allografts were than subjected to 4-h cold ischemia, and transplanted to 
WF rats. (A) Effect of single-dose VEGF-C/D trap on rat cardiac allograft survival. (B) 
Representative images for the degree of luminal arterial occlusion in Hematoxylin-
eosin and Resorcin-Fuchsin stained myocardial cross-sections. (D) Representative 
images for the extent of fibrotic area in Masson’s trichrome stained myocardial cross-
sections. Survival data are given by Kaplan-Meier survival plot, ***P<0.001 by the 
Mann-Whitney U test. 
 
In mice cardiac allografts, donor treatment with VEGFR3 blocking monoclonal 
antibody confirmed survival benefit of cardiac allografts. 
Our results suggest single-dose ex-vivo intracoronary treatment with VEGF-C/D 
inhibitor at the time of organ procurement as an alternative clinically feasible dendritic 
cell and lymphatic vessel targeted immunomodulatory approach. 
 
6 Conditional deletion of VEGFR3 in lymphatic endothelial cells of mouse 
cardiac allografts improves graft survival 
Our previous results indicated two possible targets of VEGFR3 inhibition: lymphatic 
endothelial cells and dendritic cells, both expressing VEGFR3. Thus, our next aim 
was to determine which of the VEGF-C signaling arms is primarily responsible for the 
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beneficial results of VEGFR3 inhibition on the development of alloimmune response. 
For this, a line of C57BL/6J mice with a possibility for conditional knock out of 
VEGFR3 in LECs (Vegfr3iΔLEC) was used. For knock out, the Vegfr3iΔLEC mice and 
Vegfr3flox/flox control mice were treated with i.p. injections of tamoxifen for 3 
consecutive days. Ten days after the last injection, the hearts were harvested and 
used as cardiac allografts for the heterotopic transplantation into BALB/c recipients. 
A standard setting of 4-h cold and 1-h warm ischemia before transplantation was 
used. Conditional knock out of VEGFR3 selectively in lymphatic endothelial cells of 
cardiac allografts significantly prolonged graft survival, compared with littermate 
controls (Figure 9). 
Thus, conditional deletion of VEGFR3 specifically in lymphatic endothelial cells in 
cardiac allograft donors proved that VEGF-C/VEGFR3 pathway in lymphatic 
endothelium, and not in myelomonocytic cells, is central in the bridging of innate and 
adaptive immune responses in the cardiac allografts. 
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Figure 9. Conditional deletion of Vegfr3 in lymphatic endothelial cell in the 
donor hearts improves cardiac allograft survival. Vegfr3 knock-out donor hearts 
were transplanted to balb/c mice after 4-h cold ischemic preservation. Effect of 
lymphatic specific Vegfr3 knock-out in donors on mouse allograft survival. Survival 
data are given by Kaplan-Meier survival plot, *P<0.05 by the Mann-Whitney U test. 
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DISCUSSION 
1 The evidence of a link between lymphatic endothelial phenotype and 
alloimmunity in human thoracic transplantation 
Solid organ transplantation results in complete mechanical disruption of all lymphatic 
connections of the allograft. The establishment of new connections to secondary 
lymphoid organs requires at least one to two weeks after the transplantation, as has 
been demonstrated in experimental animal trials (Málek and Vrubel 1968). This 
process is believed to require lymphatic neoangiogenesis, finally providing the 
pathway for donor antigen presentation to secondary lymphatic organs. Thus, the 
mechanisms of lymphatic reconnection between the transplanted organ and the 
recipient lymphatic system may be of special importance for understanding the 
process of donor antigen presentation and the development of alloimmune response. 
And although lymphatic biology appears to be crucial in in terminally insufficient or 
transplanted solid organs, concrete changes have not been investigated before. 
Thus, the initial purpose of Paper I was to investigate the modification of cardiac 
lymphatic endothelial cell phenotype after heart transplantation and to analyse a 
possible association of with changes with allograft rejection. 
The data demonstrated that myocardial lymphatic endothelium showed a significant 
change of phenotype after transplantation, expressed in modification of lymphatic 
receptor expression pattern. Further, lymphatic vessel activation correlated strongly 
with acute allograft rejection, as patients in acute allograft rejection after heart 
transplantation had a significantly lower density of VEGFR3+ lymphatics (Geissler et 
al. 2006). This finding can be explained by acute destruction of initial lymphatics in 
terms of general necrotic reaction of the acutely rejecting myocardium. 
In paper II we demonstrated that cardiac lymphatics in patients with terminal heart 
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failure undergo significant morphological changes compared to healthy hearts 
(Dashkevich et al. 2009). 
In paper III, the endotracheal biopsies of human lung transplant recipients were 
analysed for lymphatic angiogenesis and allograft rejection. These data were 
correlated to diverse clinical examinations during the postoperative follow up. Here, 
activated lymphangiogenesis after lung transplantation was associated with 
histologically evident allograft rejection (Dashkevich, Heilmann, et al. 2010). 
The findings in heart and lung transplant patients are opposite. Thus, it appears that 
allograft rejection can be associated with both: elevated and increased densities of 
lymphatic vessels. This controversy might be explained by differences between acute 
and chronic allograft rejection. Thus, as recently demonstrated for rejecting rat 
cardiac allografts (Nykanen et al. 2010), acute rejection decreases the epicardial 
lymphatic vessel density (mainly due to the tissue necrosis) and chronic rejection 
doubles the myocardial lymphatic vessel density (as a sequence of chronic 
inflammation). For this reason it appears to be very important to differentiate between 
the two modalities of allograft rejection. Further, these opposite findings raised the 
question whether the quantitative and qualitative changes of lymphatic endothelium 
after heart and lung transplantation are not just a secondary reaction, but might also 
reflect their regulatory role in the initiation of alloimmune reactions. 
These observations of the changes in microangiogenesis after heart and lung 
transplantation and in patients with terminal heart failure in human patients were the 
first of their kind. The core message of these studies can be summarized as follows: 
acute allograft rejection after heart and lung transplantation in human patients is 
associated with significant changes in the phenotype of lymphatic endothelium. 
As far as the studies on human patients could not reveal the exact mechanistic role 
of lymphangiogenesis in allograft rejection or clarify the relation between rejection 
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and lymphatic endothelial phenotype, the experimental studies involving heterotopic 
heart transplantation in rat and mouse were conducted. 
 
2 The role of lymphatic endothelial cell activation in the initiation of 
alloimmune responses in rat cardiac transplants. 
The initial aim of the Paper IV was to clarify the impact of the tissue damage during 
organ preservation and ischemia-reperfusion injury on the lymphatic endothelium. 
Our results confirmed the hypothesis and demonstrated that cardiac lymphatic 
endothelium responded to prolonged cold graft preservation by rapid overexpression 
of endothelial adhesion molecules ICAM-1 and VCAM-1, and VEFGR-3 already 6h 
after graft reperfusion. These results go in hand with similar processes in contact 
hypersensitivity, where inflamed lymphatic endothelium of the skin promotes the exit 
of leukocytes from tissue to afferent lymphatic routes through induced expression of 
the adhesion molecules ICAM-1 and VCAM-1 (Johnson et al. 2006). 
The described effect of prolonged cold graft ischemia was further mimicked by 
intracoronary substitution of mutant VEGF-C, if given without any cold ischemia. 
VEGF-C substitution was also leading to early overexpression of VEGFR-3, adhesion 
molecules ICAM-1 and VCAM-1 and increased mRNA production of lymphocyte 
attracting chemokine CXCL-2. These results point out that endogenous VEGF-C is 
the key protein that induces the early lymphatic activation within hours after the 
cardiac allograft reperfusion. 
These findings also strongly remind on NF-κB mediated induction of 
lymphangiogenesis in chronic inflammation, which requires the involvement of 
PROX-1 encoding pathway and needs several days until the stable overexpression 
of VEGFR-3 (FLISTER et al. 2010). Differently to chronic inflammation, our data from 
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Paper IV describe an independent phenomenon of rapid VEGF-C dependent 
activation of lymphatic endothelium without involving PROX-1 upregulation. 
In summary, ischemia-reperfusion injury led to rapid activation of cardiac lymphatic 
endothelium and made it more sensitive to VEGF-C by upregulating its core receptor 
VEGFR3, and induced the encoding of leucocyte attracting chemokines thus 
stimulating the initiation of afferent leucocyte traffic. The observed in this 
experimental setting VEGF-C mediated rapid lymphatic activation seems to repeat 
the physiological endogenous anti-inflammatory mechanism aimed at limiting edema 
formation and accumulation of inflammatory cells (Huggenberger et al. 2010). Such a 
lymphatic activation can be beneficial in acute skin inflammation (Huggenberger et al. 
2011) or even inhibit chronic skin inflammation (Huggenberger et al. 2010). Similarly, 
promotion of lymphangiogenesis is beneficial in the treatment of asthma and other 
inflammatory airway diseases (Baluk et al. 2005). Thus, it was important to further 
investigate what is the role of lymphatic endothelial cell activation in the cardiac 
allograft allogeneic environment. 
In conclusion, this is the first study to demonstrate the early acute VEGF-C mediated 
LEC activation after rat allogeneic heart transplantation. 
 
The schematic overview of the possible VEGF-C pathways, relevant for experimental 
cardiac transplantation and based on the results of paper IV, is presented in Figure 
10. 
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Figure 10. VEGF-C signaling pathways in cardiac transplantation. VEGF-C 
modifies lymphatic vessel properties by upregulating CCL21 – a chemokine that 
attracts CCR7+ dendritic cells. VEGF-C also has direct effects on VEGFR-3+ 
dendritic cells, and induces their maturation and unilateral migration through the 
lymphatic network to secondary lymphoid organs. Thus, VEGF-C plays an important 
role in the initiation of direct alloimmune recognition through direct effects on 
lymphatic endothelial cells and antigen-presenting cells. VEGF-C may also have 
angiogenic effects through VEGFR-2 binding; its role in transplantation remains 
unclear. BEC, blood endothelial cell; CCL-21, chemokine ligand 21; LEC, lymphatic 
endothelial cell; CCR-7, C-C chemokine receptor type 7; DC, dendritic cell; MHC II, 
major histocompatibility complex class II; VEGFR-2, VEGF receptor 2; VEGFR-3, 
VEGF receptor 3; TCR, T cell receptor. Figure authored by Alexey Dashkevich, 
copyright by John Wiley and Sons; reprinted with permission. 
 
3 Long-term beneficial effects of VEGF-C inhibition strategies in rat cardiac 
allografts 
Based on the previous data demonstrating the early acute VEGF-C mediated LEC 
activation, our next goal was to inhibit this endothelial activation and investigate the 
possible effects in rat cardiac allografts 
To prevent the adverse effects of VEGF-C, we treated the donor rat hearts ex vivo at 
the time of organ procurement with intracoronary administration of VEGF-C/D trap. 
According to our data, VEGF-C inhibition in donor heart prevented the early 
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lymphatic vessel activation as observed previously. Further, the single-time 
application of the VEGF-C trap prevented the activation of adaptive immune 
responses and the consequent development of cardiac fibrosis and allograft 
vasculopathy. These results appear to be of clinical importance, as cardiac allograft 
vasculopathy and rejection belong to the leading causes of death after heart 
transplantation today (Stehlik et al. 2012). Especially the long-term beneficial 
consequences of a single dose of VEGF-C/D trap for cardiac allografts seem to be 
important. 
 
The mature VEGF-C also binds and activates VEGFR-2 which can be expressed on 
both: the blood and lymphatic vascular endothelium (Joukov et al. 1996; Makinen et 
al. 2001). Thus, it was the further goal of the study to dissect whether VEGFR2 might 
also play a role in the described processes. I showed here that preoperative donor 
treatment with neutralizing monoclonal VEGFR-3 antibody ameliorated acute 
rejection response and prolonged cardiac allograft survival. This finding proved that 
the similar beneficial effects of VEGF-C/D trap are based on specific interaction with 
VEGFR-3, not involving VEGFR-2 signaling. 
Furthermore, conditional gene deletion of VEGFR3 specifically in lymphatic 
endothelial cells of heart donors proved that VEGF-C/VEGFR3 pathway in lymphatic 
endothelium, but not in myelomonocytic cells, is central in the bridging of innate and 
adaptive immune responses in the cardiac allografts. 
Here, the implication of specific conditional gene deletion of VEGFR3 in 
myelomonocytic cell line of cardiac allograft donors would be of specific interest in 
the future, as specific targeting of VEGFR3 expressing donor antigen presenting cells 
might represent a separate important therapeutic target. 
In summary, Paper IV proved that inhibition of VEGFR3-signaling in heart donor 
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allows to prevent lymphatic endothelial cell activation and dendritic cell maturation. It 
consequently reduced activation of adaptive alloimmune rejection responses and the 
development of cardiac fibrosis and allograft vasculopathy. Furthermore, single dose 
donor treatment with a monoclonal VEGFR3 antibody as well as conditional 
lymphatic specific VEGFR3 deletion in the donor heart improved graft survival. 
Importantly, the beneficial treatment did not influence the myocardial damage 
severity or innate immunity, but was exclusively based on the modification of 
adaptive alloimmune responses. These results specifically pointed out the 
pathogenetic relevance of VEGF-C-VEGFR3 signaling axis in the development of 
adaptive immune responses, thus highlighting a new therapeutic target for prevention 
of alloimmune responses.  
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SUMMARY 
Lymphatic endothelium is relevant for the pathogenesis of various cardiac and 
pulmonary diseases. However, the knowledge about the functions and role of 
lymphatic endothelium in the setting of transplantation is very limited. Therefore it 
was the main focus of this study. 
The study investigated the changes of lymphatic endothelial phenotype in patients 
with terminal heart failure and during the time course after heart and lung 
transplantation. These observations of lymphatic phenotype are the first of their kind 
and provide the evidence, that acute allograft rejection after heart and lung 
transplantation in human patients is associated with significant changes in the 
phenotype of lymphatic endothelium. To show exact mechanistic role of lymphatic 
endothelium in acute organ rejection and to clarify the cause-effect relation between 
allograft rejection and lymphatic endothelium, the experimental studies involving 
heterotopic heart transplantation in rat and mouse were conducted. The results 
demonstrated that ischemia-reperfusion injury induced the activation of lymphatic 
endothelial cells in rat cardiac allografts. The process was mediated by interaction in 
the VEGF-C-VEGFR-3 axis and had direct consequences for the development of 
alloimmune responses. Further, specific perioperative single-dose VEGF-C inhibiting 
strategies demonstrated beneficial effects on lymphatic vessel activation, antigen-
presenting cell trafficking and subsequent development of alloimmune responses in 
rat cardiac allografts. VEGF-C/D trapping in donor heart prevented acute lymphatic 
vessel activation and led to homing of VEGFR-3+ dendritic cells in cardiac allograft. 
Intracoronary ex-vivo perfusion with VEGF-C/D trap also improved rat cardiac 
allograft survival and inhibited the development of cardiac fibrosis, allograft 
vasculopathy and inflammation. 
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The results of the study, thus, demonstrate the significance of VEGF-C-VEGFR-3 
signaling in alloimmunity and suggest VEGF-C/D inhibiting strategies as an 
alternative clinically feasible immunomodulatory approach targeting lymphatic 
vessels.  
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